Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Stage IV Breast Cancer|HER2 Negative|Invasive Breast Cancer
Interventions: DRUG: Atezolizumab|DRUG: Carboplatin|OTHER: Laboratory Biomarker|OTHER: Quality-of-Life Assessment
Sponsor: Vanderbilt-Ingram Cancer Center
Collaborators: National Cancer Institute (NCI)|Genentech, Inc.